Nifty Next 50Healthcarenifty next 50
Zydus Lifesciences Share Price & Analysis
Zydus Lifesciences is a research-led pharma company with strengths in generics, vaccines, and wellness.
Live price
ZYDUSLIFE · Healthcare
₹1,119.10
+1.30 (+0.12%)
Day High
₹1,135.50
Day Low
₹1,104.60
52W High
₹1,205.00
52W Low
₹835.50
Volume today: 10.39 L
Key fundamentals
Market cap
—
P/E ratio
—
P/B ratio
—
ROE
—
Debt / Equity
—
Dividend yield
—
Revenue growth
—
Earnings growth
—
Live fundamentals from Yahoo Finance where available. Reference ratios may lag the latest quarterly results.
PaisaTamil Consensus
SELLScore 44/100 · Low confidence
Weak momentum or earnings trends suggest caution. Review position sizing and stop-loss levels.
12M Price Target
₹1,063
Low ₹929 · High ₹1,231
Analyst-style Breakdown
Strong Buy
0
Buy
0
Hold
21
Sell
1
Strong Sell
0
Derived from public market signals — price momentum, earnings trend, valuation, quality, and technical position — modelled in an analyst-style consensus format.
Signal Breakdown
Price Momentum55/100
1M -7.1%, 1Y +7.3%
Earnings Trend25/100
Latest quarter revenue ₹7.8k Cr, profit ₹940 Cr
Valuation50/100
P/E — vs sector median ~35x
Financial Quality28/100
ROE —, ROCE —
Technical Position65/100
Trading between 52W low 836 and high 1205
Modelled from public market signals — not live broker analyst data. For education only; not SEBI-registered investment advice.
Price Chart
Quarterly Results
| Quarter | Revenue | Net Profit | EPS | Rev YoY | Profit YoY |
|---|---|---|---|---|---|
| Jun 2026 | ₹7.8k Cr | ₹940 Cr | ₹9.35 | +24.0% | -19.7% |
| Mar 2026 | ₹7.4k Cr | ₹1.3k Cr | ₹12.65 | — | — |
| Dec 2025 | ₹6.8k Cr | ₹1.0k Cr | ₹10.36 | — | — |
| Jun 2025 | ₹6.5k Cr | ₹1.5k Cr | ₹14.58 | — | — |
| Mar 2025 | ₹6.3k Cr | ₹1.2k Cr | ₹11.64 | — | — |
Reference Ratios
Market Capⓘ
—
P/E Ratioⓘ
—
P/B Ratioⓘ
—
ROEⓘ
—
ROCEⓘ
—
Div Yieldⓘ
—
Company Overview
Manufactures and markets formulations in India, US, and emerging markets plus CDMO services.
Strengths
- + Diversified US and India revenue mix
- + Vaccine and complex generics pipeline
Risks
- − US pricing pressure in generics
- − FDA compliance at manufacturing facilities
Latest News
No recent news articles for Zydus Lifesciences yet. Check back after the next hourly scan.
Browse all market news →Investor Questions
Yes. Zydus Lifesciences is a current constituent of the Nifty Next 50, which represents the 50 largest Nifty 100 companies outside the Nifty 50.